USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
      Featured
      Our Next Event
      Register for LSI USA ‘26
      500+ Investors & Strategics
      See LSI USA '26 Attendee List
      Events Overview
      • Our Summits
      • Who Attends
      • Why Present
      Upcoming Summits
      • LSI USA ‘26
      • LSI Asia ‘26
      • LSI Europe '26
      Past Summits
      • LSI USA ‘25
      • LSI Asia ‘25
      • LSI Europe ‘25
      • Archives
  • Insights
      Featured
      Just Launched
      Compass AI
      New Report
      Emerging Innovators Report
      Compass Al
      Emerging Innovators Report
      Market Data
      Custom Research
  • Magazine
      Featured
      February Edition
      Explore Latest Editions
      The Lens Magazine
      Start Your Subscription
      Magazine
      • The Lens Magazine
      • Explore the Newest Edition
      • Read Free Articles
  • Resources
      Featured
      Released Weekly
      The LSI Alumni Weekly Recap
      Just Released
      2025 LSI Alumni Funding Report
      Resources
      • Research Desk
      • Testimonials
      • Video Library
      • Photo Gallery
  • Company
      Featured
      Our Next Event
      Register for LSI USA '26
      Just Launched
      Compass AI
      Company
      • About Us
      • Our Team
      • Press
  • Contact Us
Contact Us
USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
  • Insights
  • Magazine
  • Resources
  • Company
Events Overview
  • Our Summits
  • Who Attends
  • Why Present
Upcoming Summits
  • LSI USA ‘26
  • LSI Asia ‘26
  • LSI Europe ‘26
Past Summits
  • LSI USA ‘25
  • LSI Asia ‘25
  • LSI Europe ‘25
  • Archives
Featured
Our Next Event
Register for LSI USA '26
350+ Investors & Strategics
See LSI USA '26 Attendee List
Compass Al
Emerging Innovators Report
Market Data
Custom Research
Featured
Just Launched
Compass AI
New Report
Emerging Innovators Report
Magazine
The Lens Magazine
Explore the Newest Edition
Read Free Articles
Featured
February Edition
Explore Latest Editions
The Lens Magazine
Start Your Subscription
Resources
Research Desk
Testimonials
Video Library
Photo Gallery
Featured
Released Weekly
The LSI Alumni Weekly Recap
Just Released
2025 LSI Alumni Funding Report
Company
About Us
Our Team
Press
Featured
Our Next Event
Register for LSI USA '26
Just Launched
Compass AI
Join our Next Event
LSI USA ‘26, March 16-20, 2026
Waldorf Astoria, Monarch Beach
Register Today
Compass AI
The medtech-specific AI
research platform by LSI
Demo Compass AI
The Lens Magazine
The Lens Medtech
Magazine is LSI's most
curated industry coverage.
  1. Video Library
  2. Beneath the Tip of the Fundraising Iceberg: What Challenges Come After Getting the Verbal Yes? | LSI Europe '23

Beneath the Tip of the Fundraising Iceberg: What Challenges Come After Getting the Verbal Yes? | LSI Europe '23

In this panel, the speakers discuss challenges and provide insights about what happens after getting a verbal 'Yes' from potential investors.
Share social-facebook social-x social-linkedin
Speakers
Adam Rosenwach
Adam Rosenwach
Chief Business Officer, Deerfield Catalyst
Bio Bio
Todd Usen
Todd Usen
President & CEO, Minerva Surgical
Bio Bio
Claire Masterson
Claire Masterson
CFO, Caresyntax
Bio Bio
Kyle Faget
Kyle Faget
Partner, Foley & Lardner
View Video Transcript
lsi logo
Contact Us

Upcoming Events

LSI USA ‘26
LSI USA ‘26
March 16-20, 2026
Dana Point, CA
LSI ASIA ‘26
LSI ASIA ‘26
June 30 - July 2, 2026
Singapore
LSI EUROPE ‘26
LSI EUROPE ‘26
Sept 28 - Oct 1, 2026
Barcelona

More From LSI

  • Attend an Event
  • Sponsor an Event
  • Compass, by LSI
  • The Lens, Magazine by LSI

Resources

  • Research Desk
  • Photo Gallery
  • Video Library
  • Testimonials
  • About Us

17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647

714-847-3540

© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy

Request Info
close
STEP 1
close-icon
The Lens - Complimentary Issue
close
close

Subscription Includes

Request Info

Global Medtech Market Analysis & Projections (MAP), 2021-2031
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf report

The Global Medtech Market Analysis and Projections (MAP) provides global market forecasts (2021 – ’31), share-by-supplier data, and analyst insights on 23 major device markets (e.g., Cardiovascular, Orthopedics, Neurovascular, In-Vitro Diagnostics) and 200+ technology subsegments. Understand major market trends and projections across the medtech industry with what medtech strategics and consulting firms have referred to as their “gold standard” for device market sizing data.

Global Surgical Procedure Volumes Dashboard, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Global Surgical Procedure Volumes database is the single source of truth for understanding diagnostic and therapeutic procedure volumes on a global scale. With coverage on 37 countries, including the United States, Europe’s Big Five, China, India, Japan and more for 12 major procedure markets (Cardio, Ortho, General Surgery, Radiosurgery, Neuro, OB/GYN and more), this fully interactive database is designed to facilitate one-to-one analyses of procedures, countries, and regions. Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

United States Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United States Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United States. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Aesthetics, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Aesthetics Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Aesthetics Procedures Database covers major aesthetic procedures, including: Biopsies, Punch Biopsies, Shave Biopsies, Incisional Biopsies, Lesion Removal Procedures, Curettage, electrocautery, and electrocoagulation lesion destruction, Photodestruction, Cryotherapy-based lesion destruction, Lesion Removal Procedures: Traditional and Other, Abdominoplasty, Blepharoplasty, Breast Augmentation, Breast Lift, Breast Reduction, Buttock Augmentation, Buttock Lift, Cheek Implants, Chin Augmentation, Facelift, Forehead Lift, Gynecomastia Treatment, Hair Transplantation, Lip Augmentation, Liposuction, Lower Body Lift, Otoplasty, Rhinoplasty, Thigh Lift, Upper Arm Lift, Vaginal Rejuvenation, Surgeries for Cleft Palate and Lip, Surgeries for Burn Injuries.

Cardio, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Cardiothoracic and Interventional Cardiology Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Cardiothoracic and Interventional Cardiology Procedures Database covers major cardiothoracic and interventional cardiology procedures, including: CABG Surgeries Off-Pump CABG, On-Pump CABG, Valve Procedures Aortic Valve Replacements, Mitral Valve Replacements, MV Repairs, AV Repairs, PV Replacements, PV Repairs, TV Operations, Percutaneous Valvuloplasties, Percutaneous Valve Replacements, CHD Surgeries Ventricular Septal Defect Closures, Patent Ductus Arteriosus Repairs, Atrial Septal Defect Closures, Repair of Tetralogy of Fallot, Arterial Shunts Surgeries, Atrioventricular Septal Defect Repairs, Transposition of Great Artery Procedures, Anomalous Pulmonary Venous Return Repairs, Other Congenital Heart Disease Surgeries, Other Cardiothoracic Surgeries Aortic Aneurysm Procedures, Other Cardiothoracic Surgeries, Diagnostic and Therapeutic Catheterizations, Stand-Alone Diagnostic Cardiac Catheterizations, Percutaneous Coronary Interventions, Coronary Interventions Radial Approach, Coronary Interventions Femoral Approach, Heart Rhythm Procedures Conventional Pacemaker Procedures, ICD Procedures, Cardiac Resynchronization Device Procedures, Combined Defib/Resynch Device Procedures, Cardiac Ablations.

ENT, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ear, Nose, and Throat Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ear, Nose, and Throat Surgical Procedures Database covers major ear, nose, and throat procedures, including: Tonsillectomies, Operations on the Ear, FESS, Tracheostomies, Thyroidectomies & Parathyroidectomies, Stand-Alone Adenoidectomies, Tongue Operations, Laryngeal Operations, Pharyngeal Operations, Radical Neck Dissection.

General, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The General Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The General Surgeries Procedures Database covers major general surgical procedures, including: Cholecystectomies Laparoscopic Cholecystectomies, Open Cholecystectomies, Appendectomies, Laparoscopic Appendectomies, Open Appendectomies, Herniorrhaphies Laparoscopic Herniorrhaphies, Open Herniorrhaphies, Bariatric Surgeries Laparoscopic Bariatric, Open Bariatric, Selected Other Endoscopic General & Colorectal Procedures Esophageal (Other Endoscopic), Stomach & Intestinal (Other Endoscopic), Colorectal (Other Endoscopic), Liver (Other Endoscopic), Gallbladder & Biliary (Other Endoscopic), Pancreatic (Other Endoscopic), Other (Other Endoscopic), Other Surgeries Esophageal (Other General, non-Endoscopic), Stomach & Intestinal (Other General, non-Endoscopic), Colorectal (Other General, non-Endoscopic), Liver (Other General, non-Endoscopic), Gallbladder & Biliary (Other General, non-Endoscopic), Pancreatic (Other General, non-Endoscopic), Other (Other General, non-Endoscopic).

Neuro, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Neurosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Neurosurgery Procedures Database covers major neurosurgical procedures, including: Surgeries for Traumatic Brain Injuries, Ventricular & Shunt Surgeries, New Shunt Placements, Revision Shunt Surgeries, Endoscopic Third Ventriculostomies, Diagnostic Ventricular Endoscopies, Vascular Lesion Procedures, Vascular Lesion Surgeries, Vascular Lesion Coil Procedures, Pituitary Tumor Surgeries, Open Pituitary Tumor Surgeries, Endoscopic Pituitary Tumor Surgeries, Intracranial Tumor Surgeries, Open Intracranial Tumor Surgeries, Endoscopic Intracranial Tumor Surgeries, Cranioplasties, Intracranial Neurostimulation and Peripheral Nerve Procedures, Intracranial Neurostimulator Implant Procedures, Peripheral Nerve Neurostimulation Procedures, Other Peripheral Nerve Procedures.

OB/GYN, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Obstetric and Gynecological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Obstetric and Gynecological Surgical Procedures Database covers major obstetric and gynecological procedures, including: Obstetrical Surgeries Cesarean Sections, Destructive Operations, Episiotomies, Other Obstetrical Surgeries, Gynecological Surgeries Colposcopies, Hysterectomies, Salpingo-Oophorectomies & Oophorectomies, Colposcopies, Salpingo-Oophorectomies & Oophorectomies, Hysterectomies, Total Hysterectomies, Subtotal Hysterectomies, Vaginal Hysterectomies, Breast Cancer Surgeries, Breast Reconstruction Surgeries, Breast-Conserving Surgeries, and Mastectomies, among other surgeries.

Ophthalmology, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ophthalmological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ophthalmological Surgical Procedures Database covers major ophthalmological procedures, including: Cataract Surgeries, Phacoemulsification Surgeries, ICCE Surgeries, ECCE Surgeries, MSICS Surgeries, Refractive Surgeries.

Orthopedic, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Orthopedic Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Orthopedic Surgical Procedures Database covers major orthopedic procedures, including: Hip Arthroplasties Revision Hip Arthroplasties, Hip Resurfacing Procedures, Primary Hip Arthroplasties - Total Hip, Partial Hip, Knee Arthroplasties Revision Knee Arthroplasties, Primary Knee Arthroplasties - Partial Knee, Primary Knee Arthroplasties - Total Knee, Extremity Fractures Using Hardware Extremity Fractures Using Hardware - Upper Extremities, Extremity Fractures Using Hardware - Fractures of the Femoral Neck & Shaft, Extremity Fractures Using Hardware - Other Lower Extremity, Arthroscopies Knees (Arthroscopies), Shoulders (Arthroscopies), Ankles (Arthroscopies), Feet & Toes (Arthroscopies), Others (Arthroscopies), Other Joint Arthroplasties Finger & Hand, Wrist, Elbow, Shoulder, Ankle & Foot.

Peripheral Vascular, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Peripheral Vascular Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Peripheral Vascular Surgeries Procedures Database covers major peripheral vascular procedures, including: Arterial Procedures Thrombectomies & Thromboendarterectomies, Carotid Artery Thrombectomies, Upper Limb Artery Thrombectomies, Iliac Artery Thrombectomies, Renal Artery Thrombectomies, Lower Limb Artery Thrombectomies, Arterial Angioplasties, Carotid Artery Angioplasties, Upper Limb Artery Angioplasties, Iliac Artery Angioplasties, Renal Artery Angioplasties, Lower Limb Artery Angioplasties, Arterial Bypasses, Carotid Artery Bypasses, Upper Limb Artery Bypasses, Iliac Artery Bypasses, Renal Artery Bypasses, Aortofemoral and Aortobifemoral Bypasses, Femoropopliteal Bypasses, Femorotibeal Bypasses, Other Lower Limb Bypasses, Venous Procedures Head, Neck, & Upper Limb Thrombectomies & Thromboendarterectomies of Dialysis Access Venous Segments, Thrombectomies & Thromboendarectomies of Other Upper Limb Veins, Angioplasties of Dialysis Access Venous Segments, Angioplasties of Head, Neck and Other Upper Limb Veins, Lower Limb Venous Procedures Removals of the Saphenous Vein, Removals of Other Veins of the Lower Limbs.

Spine, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spine Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Spine Surgical Procedures Database covers major spine procedures, including: Cervical Spine Surgeries Cervical Spine Decompressions, Cervical Spine Discectomies, Cervical Spine Fusions, Cervical Spine Disc Replacements, Thoracic and Deformity Procedures Thoracic Spine Decompressions, Thoracic Spine Discectomies, Thoracic Spine Fusions, Instrumented Procedures for Deformities, Lumbar Procedures Lumbar Spine Decompressions, Lumbar Spine Discectomies, Lumbar Spine Fusions, Insertion of Lumbar Interspinous Process Spacer, Lumbar Spine Disc Replacements, Vertebroplasties & Kyphoplasties Vertebroplasties, Kyphoplasties, Other Spine Surgeries.

SRS, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Stereotactic Radiosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Stereotactic Radiosurgery Procedures Database covers major stereotactic radiosurgery procedures, including: Intracranial SRS Procedures, Extracranial SRS Procedures, Extracranial Spine Procedures, Extracranial Lung Procedures, Other Extracranial Procedures.

Urological, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Urological Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Urological Surgeries Procedures Database covers major urological procedures, including: Kidney Stone Procedures Extra Corporeal Shock Wave Lithotripsy, Percutaneous Nephro Lithotripsy, Ureteroscopies, Open Kidney Stone Procedures, BPH Procedures Transurethral Prostatectomies, Other BPH Surgeries, Prostatectomies, Nephrectomies Partial Nephrectomies, Radical Nephrectomies, Bladder Procedures Therapeutic Endoscopies, Diagnostic Endoscopies, Urethral Catheterizations of Bladder.

Global Markets for Hip Replacement Implants, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for hip replacement implants. The market for hip replacement implants includes all prosthetic devices used to replace damaged sections of the hip joint, including those used in total and semi/hemi replacement procedures. This market snapshot is intended to provide a high-level overview of the global market for hip replacement implants, with key insights into: Procedure volumes from 2022 to 2028, Market forecasts from 2022 to 2028, Competitive landscape analysis of major competitors, Insights into key market events for strategics and startups. Companies covered in this report include: B. Braun, DePuy Synthes, DJO Global, Exactech, Johnson & Johnson, Medacta, MicroPort Scientific, Ortho Development, OSSIS, SERF SAS, Smith+Nephew, Symbios Orthopedie, Total Joint Orthopedics, Zimmer Biomet.

Global Markets for Peripheral Vascular Guidewires, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Atherectomy Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Electrosurgery, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Vascular Balloons & Vena Cava Filter, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for percutaneous transluminal angioplasty (PTA) balloons and inferior vena cava (IVC) filters. A PTA balloon is used in the treatment of peripheral artery disease (PAD) to open a narrowed or blocked artery. IVC filters are permanent or temporary devices to prevent the travel of thrombotic material to the lungs. These devices are frequently used in the management of patients with severe PAD. This market snapshot is intended to provide a high-level overview of the global market for PTA balloons and IVC filters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Acotec Scientific, Adient Medical, B. Braun, BD, Biotronik, Boston Scientific, Brosmed, Cagent Vascular, Cardinal Health, CONMED, Cook Medical, Concept Medical, Cordis, Covellus, Degania Medical, iVascular, Medtronic, Merit Medical, NextStep Medical, Nipro, OrbusNeich, Orchestra BioMed, Philips, Terumo, TriReme Medical.

Global Markets for Mechanical Heart Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Tissue Heart Valve Replacement, 2023-2028
Published:
2023
Next Update:
Q2 2030
Deliverables:
excel pdf

Description coming soon.

Global Markets for Transcatheter Mitral Valve Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Femoral Closure, 2023-2029
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for femoral closure devices. Femoral closure devices are used to achieve hemostasis of the hole in the artery that is created to perform catheter-based cardiovascular or endovascular procedures. This market snapshot is intended to provide a high-level overview of the global market for femoral closure devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Cardinal Health, Cardiva, Cordis, CyndRx, Endocor, Haemonetics, Morris Innovative, Rex Medical, Teleflex, Terumo, Transluminal Technologies, Vasorum, Vivasure Medical.

Global Markets for Tricuspid Valve Repair, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for tricuspid valve repair devices. Tricuspid valve repair is the preferred surgical approach for the treatment of degenerative tricuspid valve disease. The market is currently experiencing a renaissance with the introduction and development of transcatheter solutions for tricuspid valve repair and replacement. Devices covered within the scope of this analysis include tricuspid valve annuloplasty rings and transcatheter tricuspid valve repair devices. This market snapshot is intended to provide a high-level overview of the global market for tricuspid valve repair devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, CroiValve, Edwards Lifesciences, Innoventric, Medtronic, Mitral Holdco, Mitralix, NaviGate, OrbusNeich, TriCares, Venus Medtech.

Global Markets for Percutaneous Pulmonary Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for transcatheter pulmonary valve devices. Pulmonary valve replacement is performed primarily for the treatment of pulmonary valve stenosis, a relatively rare disease associated with congenital heart defects. Devices covered within the scope of this analysis include transcatheter pulmonary valve implants for valve repair and replacement. This market snapshot is intended to provide a high-level overview of the global market for transcatheter pulmonary valve devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Edwards Lifesciences, Medtronic, PolyVascular, Venus Medtech.

Global Markets for Coronary Angio Guidewires & Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for coronary angiography catheters and guidewires. These devices are essential to perform coronary angiography, a minimally invasive medical procedure used to visualize blood flow, identify blockages and narrowing of the coronary arteries. Devices covered within the scope of this analysis include coronary angiography catheters and coronary angiography guidewires. This market snapshot is intended to provide a high-level overview of the global market for coronary angiography catheters and guidewires, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AngioDynamics, B. Braun, Boston Scientific, Cardinal Health, Cook Medical, Cordis, Medtronic, Merit Medical, Philips, Teleflex, Terumo.

Global Markets for Oncology Ablation Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology ablation catheters. These devices are used as a therapeutic modality employing energy to selectively destroy cancerous tissue. Devices covered within the scope of this analysis include radiofrequency and microwave ablation electrodes, excluding cryoablation devices, which are covered in a separate report. The snapshot offers a high-level overview of the global market for oncology ablation catheters and guidewires, with key insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: AngioDynamics, Baylis, Boston Scientific, Canyon Medical, CAPS Medical, EDAP, Galvanize Therapeutics, Imagin Medical, Medtronic, Mermaid, Mirai Medical, Monteris, Sonablate, Stryker, TROD Medical, and US Medical Innovations.

Global Markets for ENT Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for endoscopic devices for ear, nose, and throat (ENT) surgery. These devices are used to examine and operate on the structures and tissues in the ear, nose, and throat. Devices covered within the scope of this analysis include ENT endoscopic surgical instruments, balloon sinus and dilation catheters, and rigid endoscopes and bronchoscopes. This market snapshot is intended to provide a high-level overview of the global market for ENT endoscopic surgery devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: 3NT Medical, Acclarent, Conmed, Endoluxe, Entellus Medical, Intuitive Surgical, Johnson & Johnson, KARL STORZ, Medtronic, Olympus, Pentax, Pristine Surgical, Richard Wolf, Smith & Nephew, Stryker, Tympany Medical.

Global Markets for Cell Delivery Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cell delivery catheters. These devices are primarily research-use devices for the delivery of cellular therapies for the treatment of chronic diseases, such as cardiovascular disease and cancer. Devices covered within the scope of this analysis include cell delivery catheters. This market snapshot is intended to provide a high-level overview of the global market for cell delivery catheters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: BioCardia, Biosense Webster, Boston Scientific, Cordis, Medtronic, Mercator MedSystems, TriSalus Life Sciences, TRI Medical.

Global Markets for Urology Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for urology and renal devices, focusing on treatments for six major conditions: End-stage renal disease (ESRD), Incontinence, Calculi (stones), Benign prostatic hyperplasia (BPH), Prostatitis, and Erectile dysfunction (ED). The devices covered within this analysis encompass a range of tools for diagnosis, treatment, and management, including urinary bags, foley catheters, catheter insertion kits, intermittent catheters, endourology devices, BPH ablation devices, lithotripsy devices, and artificial penis devices. The snapshot provides key insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: 3M, Applied Medical, Astratech, Balton, Baxter Healthcare, B. Braun, BD, Boston Scientific, Calyxo, Corinth Medtech, Coloplast, EndoMed, Flume Catheter Company, Hollister, ICU Medical, Karl Storz, Medline, Medtronic, Merit Medical, Nipro, Olympus, SonoMotion, Teleflex, and Urovision.

Global Markets for External Pain Pumps, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for external pain pumps. These devices are used to provide patients with consistent, long-lasting pain relief by delivering pain medication epidurally, intravenously, or subcutaneously. Devices covered within the scope of this analysis include external infusion pumps for pain management. This market snapshot is intended to provide a high-level overview of the global market for external pain pumps, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Avanos, B. Braun, BioQ Pharma, Epic Health, ICU Medical, InfuTronix, Medical Flow Systems, Medipacs, MicroPort, Smiths Medical, Teleflex.

Global Markets for Ureteral Access Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence delves into the global market for ureteral access devices, crucial components utilized alongside ureteroscopy or percutaneous nephrolithotomy procedures. These devices facilitate dilation and create a working channel for various urologic interventions. The snapshot aims to offer insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it provides a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Amecath, Applied Medical, BD, Boston Scientific, Cook Medical, Envaste, Johnson & Johnson, Mednova, Olympus, Richard Wolf, Rocamed, Teleflex, and Terumo.

Global Markets for Pelvic Floor Repair, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for pelvic floor repair mesh. These products are used during surgical procedures to repair prolapse and urinary incontinence. Devices covered within the scope of this analysis include pelvic floor repair/reconstruction mesh. This market snapshot is intended to provide a high-level overview of the global market for pelvic floor repair mesh, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: BD, Boston Scientific, Coloplast, Cook Medical, Ethicon, Johnson & Johnson.

Global Markets for Atrial Fibrillation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Neurovascular Devices Ischemic, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence analyzes the global market for devices used in the treatment of ischemic stroke, focusing on solutions designed to remove occlusions in blood vessels to prevent and treat this condition. The market snapshot offers insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Cerenovus, Ceretrieve, Cordis, InNeuroCo, Julier, Medtronic, MicroPort Scientific, Microvention, Penumbra, Phenox, Poseydon Medical, Route 92 Medical, Stryker, and Terumo.

Global Markets for Neuromodulation Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global neuromodulation market – a thriving market for managing and treating neurological diseases, chronic pain, and other chronic conditions. Types of neuromodulation, or neurostimulation, devices include implantable and transcutaneous devices, including wearable devices. This market snapshot is intended to provide a high-level overview of the global neuromodulation market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bionics, Alyve Medical, Axonics, Biotronik, Boston Scientific, EBT Medical, electroCore Medical, Inspire Medical, LivaNova, Medtronic, Neuromod Devices, Nevro.

Global Markets for Vertebroplasty Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vertebral augmentation products, which are crucial in treating vertebral compression fractures, often caused by osteoporosis or spinal tumors. Vertebroplasty and kyphoplasty are the primary surgical interventions, and the market includes products such as vertebroplasty and kyphoplasty cement, as well as delivery devices. The snapshot aims to provide a comprehensive overview of the global vertebral augmentation products market, with key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Halma, IZI Medical, Medtronic, Mendec, Merit Medical, RevBio, and Stryker.

Global Markets for TAVI/TAVR, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Drug Delivery, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Benign Prostation Hyperplasia Implants, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for implants for the treatment of symptomatic benign prostatic hypertrophy/hyperplasia (BPH). These implants are reversible solutions for men suffering from lower urinary tract symptoms (LUTS) caused by prostate enlargement. This market snapshot is intended to provide a high-level overview of the global BPH implants market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Butterly Medical, Endotherapeutics, Olympus, ProArc, ProVerum, Teleflex, Urotronic, ZenFlow.

Global Markets for Cryoablation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for cryoablation devices for non-cardiovascular applications. These devices are used to freeze and induce cellular damage and death for indications including cancer, dermatological conditions, peripheral vascular disease, and urological conditions. This market snapshot is intended to provide a high-level overview of the global cryoablation devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Boston Scientific, Brymill Cryogenics, Channel Medsystems, CooperSurgical, CPSI Biotech, CryoConcepts, CryoProbe, CryoSurgery, CSA Medical, Endocare, Endocision, Grand Cryo, Ictero Medical, KryoLife, Mectronic Medical, Sedivention, Siemens Healthineers, Varian Medical Systems, Wallach Surgical.

Global Markets for Diagnostic Electrophysiology Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for diagnostic electrophysiology catheters. These devices are used to measure and map electrical activity within the heart to identify aberrant electrical activity that causes arrhythmias. LSI projects that this market will remain in a high growth phase due to improving technology for the surgical treatment of cardiac arrhythmias and atrial fibrillation (AF). This market snapshot is intended to provide a high-level overview of the global diagnostic electrophysiology catheters market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AccuPulse, Acutus Medical, BD, Biosense Webster, Boston Scientific, CardioNXT, CoreMap, Johnson & Johnson, Kardium, Medtronic, MicroPort Scientific, Stereotaxis.

Global Markets for Hernia Repair, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence (LSI) provides an analysis of the global market for hernia mesh products for the surgical repair of hernias. The global market for hernia mesh products is projected to see moderate growth throughout the forecast period covered by the analysis. While the market has been negatively impacted by ongoing lawsuits associated with product complications, the next generation of products has helped the market to recover for one of the most performed abdominal surgeries. This market snapshot is intended to provide a high-level overview of the global market for hernia mesh products, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Allergan, Ariste Medical, BD, Cook Medical, Deep Blue Medical Advances, Ethicon, Exogenesis, Integra Lifesciences, Johnson & Johnson, LifeCell, Medtronic, Novus Scientific, Tarian Medical, TELA Bio, TISSIUM, W.L. Gore.

Global Markets for CRM Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac rhythm management (CRM) devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy devices (CRT-Ds). These implantable devices are used to restore the natural rhythm and function of the heart that can be impaired as a result of cardiac rhythm disorders and heart failure. This market snapshot is intended to provide a high-level overview of the global CRM devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AtaCor Medical, BioTrace Medical, Biotronik, Boston Scientific, Cairdac, Electroducer, FineHeart, Lepu Medical, LivaNova, Medico, Medtronic, Merit Medical, Microport Scientific, Osypka Medical, Pacetronix.

Global Markets for Neurovascular Devices Hemorrhagic, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for neurovascular devices for the treatment of hemorrhagic stroke. These solutions are used to treat intracerebral bleeds, ruptured aneurysms, and other neurovascular deformities that lead to the pooling of blood vessels that have ruptured inside and outside of the brain. This market snapshot is intended to provide a high-level overview of the global market for neurovascular devices for hemorrhagic stroke, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Acandis, Artio Medical, Endostream Medical, Medtronic, MicroPort Scientific, Microvention, Phenox, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo, Wallaby Medical.

Global Markets for Renal Denervation, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for renal denervation devices for the treatment of refractory hypertension (i.e., high blood pressure that does not respond to pharmaceuticals). The market for renal denervation devices includes radiofrequency and ultrasound catheters which are used to ablate the renal nerves. This market snapshot is intended to provide a high-level overview of the global market for renal denervation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Ablative Solutions, Brattea, Medtronic, Metavention, Otsuka Medical, ReCor Medical, SoniVie.

Global Markets for Upper+Lower Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence analyzes the global market for suture anchors used in upper and lower extremity repair and reconstruction procedures. Suture anchors play a critical role in securing soft tissue to bone, particularly for severe soft tissue tears. The market encompasses bioabsorbable, biocomposite, metallic, and PEEK suture anchors. The snapshot aims to offer insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Acumed, Acuitive Technologies, aevumed, Anika Therapeutics, Arthrex, ConMed, DePuy Synthes, Johnson & Johnson, Mitek, OSSIO, Paragon 28, Responsive Arthroscopy, Riverpoint Medical, Smith & Nephew, Stryker, and Zimmer Biomet.

Global Markets for Peripheral Stents, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for biliary and peripheral vascular stents. These devices are used to maintain and restore patency to anatomical ducts or vessels that have become obstructed due to the formation of plaque, narrowing of the natural lumen, or presence of benign and malignant growths. This market snapshot is intended to provide a high-level overview of the global peripheral vascular and biliary stents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, BD, Biotronik, Boston Scientific, Bryan Medical, Cardinal Health, Cook Medical, Cordis, Endo GI Medical, Hood Labs, Maquet, Medtronic, Merit Medical, MicroPort Scientific, Olympus, Q3 Medical, Zorion Medical.

Global Markets for Electromagnetic Navigation Systems, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for electromagnetic navigation systems for tracking, guiding, and positioning instruments during surgery. These systems provide surgeons and the surgical team with real-time information on the position and orientation of instruments used during open and minimally invasive surgeries. This market snapshot is intended to provide a high-level overview of the global electromagnetic navigation systems market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Brainlab, Collin Medical, Elucent Medical, Fiagon, Heal Force, Joimax, Karl Storz, Medtronic, Olympus, Stryker, Veran Medical Technologies.

Global Markets for GI Endoscopy, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot report from Life Science Intelligence provides an analysis of the global market for gastrointestinal (GI) endoscopic devices. These devices are used to visualize, diagnose, and surgically treat conditions of the GI tract. The market for GI endoscopic devices includes endoscopes and endoscopic instruments. This market snapshot is intended to provide a high-level overview of the global market for GI endoscopic devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Ambu, Applied Medical, Aqua Medical, Aspero Medical, B. Braun, Boston Scientific, ConMed, Endoluxe, Ethicon, Integra Lifesciences, Intuitive Surgical, IQ Endoscopes, Johnson & Johnson, Karl Storz, Medtronic, MiWendo Solutions, Olympus, Purple Surgical, Richard Wolf, Stryker, Teleflex.

Global Markets for Hemodialysis, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for hemodialysis solutions. Hemodialysis is an essential treatment for patients suffering from end-stage renal disease due to kidney failure. Hemodialysis systems, catheters, and dialyzers are components integral to hemodialysis treatment. This market snapshot is intended to provide a high-level overview of the global hemodialysis solutions market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Asahei Kasei, AngioDynamics, B. Braun, Baxter, Bellco, Byonyks, Diality, Fresenius, Hemoclean, Humacyte, Intermedt, Inspira Health, iRen-MEDICAL, Medivators, Merit Medical, NextKidney, Nikkiso, Nipro, Rockwell Medical, Telelfex, Terumo, Toray Medical, TVA Medical, Vantive.

Globals Markets for Cardiac Ablation, 2023-2028
Published:
Next Update:
Deliverables:

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac ablation devices, which are used for the treatment of arrhythmic heart conditions, such as atrial fibrillation. The market for cardiac ablations devices is projected to see strong growth throughout the forecast period covered by this analysis, driven by demographic trends and the adoption of new technologies for the treatment of new ablation technologies, such as Pulsed Field Ablation. Devices covered within the scope of this analysis include cardiac ablation catheters. This market snapshot is intended to provide a high-level overview of the global market for cardiac ablation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Adagio Medical, AtriAN Medical, AtriCure, Biosense Webster, Boston Scientific, Electrophysiology Frontiers, Field Medical, Galvanize Therapeutics, Healium Medical, Johnson & Johnson, Medtronic, Stereotaxis.

Global Markets for Atrial Septal Occlusion, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for atrial septal occlusion devices. These devices are used to close atrial septal defects (ASDs), an abnormal hole in the wall of the upper chambers of the heart that are present at birth. This market snapshot is intended to provide a high-level overview of the global ASD occlusion devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, atHeart Medical, Cardia, Hanyu Medical, Lifetech Scientific, Occlutech, W.L. Gore.

Global Markets for Aortic Grafts, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for aortic stent grafts for the treatment of aortic aneurysm. The market for aortic stent grafts includes open (surgical) and endovascular (transcatheter) aortic stent grafts used in the repair of abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). This market snapshot is intended to provide a high-level overview of the global market for aortic stent grafts, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Cook Medical, Endoron, Endospan, Lombard Medical, Medtronic, MicroPort Scientific, Taurus Vascular, Terumo, TripleMed, W.L. Gore.

Global Markets for Interventional Cardiology Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for interventional cardiology devices for the treatment of cardiovascular diseases such as heart failure or severe atherosclerosis. The market for interventional cardiology devices includes devices used to diagnose and treat diseases related to the coronary arteries. Devices included within the scope of this report include coronary stents, catheters, angioplasty balloons, guidewires, and intravascular ultrasound catheters. This market snapshot is intended to provide a high-level overview of the global market for interventional cardiology devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bifurcation Systems, B. Braun, BD, Boston Scientific, Cardinal Health, Cook Medical, Corflow Therapeutics, Fastwave Medical, Lemaitre Vascular, Medtronic, Merit Medical, MicroPort Scientific, NirvaMed, Philips, Teleflex, Terumo, Translumina.

Global Markets for Oncology Embolization, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology embolization agents, including radioembolization, chemoembolization, and particle embolization devices. These solutions are used to occlude blood vessels to lesions and tumors to derive the target of nutrients, enhance the effectiveness of the targeted delivery of pharmaceuticals, and trigger cell death. This market snapshot is intended to provide a high-level overview of the global oncology embolization agents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: ABK Biomedical, Arsenal Medical, Boston Scientific, Cook, Cordis/Cardinal Health, Instylla, Medtronic, Merit Medical, Ned Medical, Obsidio, SirTex Medical, Stryker, Terumo, Varian.

Global Markets for Vascular Access Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vascular access devices, which are essential for continuous and long-term access to the bloodstream for administering intravenous drugs and fluids. The market encompasses various types of devices, including peripherally inserted central catheters (PICC), midline catheters, central venous catheters (CVC), and implantable ports. The snapshot aims to provide a comprehensive overview of the global market for vascular access devices, offering key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Access Vascular, AngioDynamics, B. Braun, Baxter, Becton, Dickinson & Company (BD), Bluegrass Vascular, C.R. Bard, Cook Medical, ICU Medical, Medline, Smiths Medical, Teleflex, Terumo, Vygon, and Yushin Medical.

Global Markets for Rotator Cuff Repair Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for rotator cuff repair suture anchors for the treatment of rotator cuff injuries. The market for rotator cuff repair suture anchors includes anchors composed of biocompatible polymers and metals. This market snapshot is intended to provide a high-level overview of the global market for rotator cuff repair suture anchors, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Aevumed, Arthrex, Atreon Orthopedics, ConMed, DePuy Synthes, Embody, Inovedis, Smith & Nephew, Stryker, Tetrous, Wright Medical, Zimmer Biomet.

Global Markets for Electrical Stimulation Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Wearable Monitoring Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Low Complexity Medical Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Canada Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Canada Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Canada. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Germany Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Germany Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Germany. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

France Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The France Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for France. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

U.K. Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United Kingdom Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United Kingdom. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Italy Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Italy Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Italy. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Spain Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spain Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Spain. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Poland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Poland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Poland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Netherlands Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Netherlands Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Netherlands. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Belgium Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Belgium Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Belgium. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Sweden Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Sweden Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Sweden. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Switzerland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Switzerland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Switzerland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Denmark Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Denmark Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Denmark. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Finland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Finland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Finland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Norway Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Norway Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Norway. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

China Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The China Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for China. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

India Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The India Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for India. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Japan Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Japan Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Japan. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Korea Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Korea Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Korea. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Australia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Australia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Australia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Thailand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Thailand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Thailand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Malaysia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Malaysia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Malaysia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Singapore Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Singapore Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Singapore. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

New Zealand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The New Zealand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for New Zealand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Caribbean Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Caribbean Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Caribbean region. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Argentina Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Argentina Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Argentina. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Colombia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Colombia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Colombia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Chile Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Chile Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Chile. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Guatemala Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Guatemala Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Guatemala. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Dominican Republic Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Dominican Republic Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Dominican Republic. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Costa Rica Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Costa Rica Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Costa Rica. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Panama Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Panama Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Panama. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Mexico Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Mexico Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Mexico. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Brazil Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Brazil Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Brazil. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Turkey Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Turkey Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Turkey. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Russia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Russia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Russia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Africa Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Africa Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Africa. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.
Schedule Meeting
Request Info
close
Video Transcription
close

 


Transcription


Adam Rosenwach  0:05  
Hi, everyone, thanks for joining for the panel. So we were speaking about putting together a panel that was going to be something different at this conference, something different than hearing VCs talk about what they're looking for, or hearing kind of how to help, how to lead a company and how to de risk it. We'd love to talk about something that's kind of a black box for most employees in a company, which is after you have commitment from your first investor, what do you do to make sure that that deal closed closes and you're going to start a good relationship with these partners. So I have a great panel here. We have a great panel here. I'm Adam Rosenwach. I started as a musician. I was a music producer. Then I ended up with the Curtea team as their bookkeeper. And now we're 12 years later and I'm Chief Business Officer of Deerfield catalyst, which is a joint venture between Deerfield management, the venture fund and createa. So why don't we go down the line with introductions and we'll kick it off.


Todd Usen  1:11  
Hello, my name is Todd Usen. I'm the president and CEO of Minerva Surgical maneuver surgical is a publicly traded women's health company located in California and focusing on on uterine health and pelvic health. And I've been 30 year medtech. industry veteran, I guess I cut my teeth at Boston Scientific I spent about 13 years there. And my last role around the United States and the neurovascular space stayed at big companies. From there I went to Smith and Nephew and one of the top four orthopedic companies located here in Europe, and had the opportunity my last role there I was the president of all of orthopedics, leading both trauma, joint and sports medicine. And then I was recruited to another big company Olympus where I was the president of all the medical divisions at Olympus, and we went from six divisions to 12. So why am I in a panel that says, What do you do after you get the verbal? Yes, I then went to the dark side and really enjoyed it. And I went to startup world and I was the CEO of a first CEO with Activ Surgical and active surgical had completed the world's first fully autonomous robotic procedure of soft tissue with advanced visualization and AI and software took that technology raised 92 million from concept to now it's commercial being sold and purchased in hospitals, and partnered with some of the scope and robotic companies in the world. So and then I came to Minerva Surgical, going a little back to the bigger roots, and still need to talk about some verbal yeses, even in this role. So it's nice to be here.


Claire Masterson  2:37  
Excellent. So I'm Claire Masterson. I'm the current CFO of Caresyntax. Although I stunt I'd say 50% of my career on the other side of the table, so starting off in financial services working for a very large family office. So I've seen things from the other side. And then from there moved into more commercial companies. So always in a finance role. So Stellar Lumens Greer, which was a listed allergy immunotherapy specialist, and then into the world of venture with care syntax for the last four years where I supported them raising about 180 million over the last three years. So how I feel I felt like I've pretty much spent the entire last three years rate fundraising in some form, or other so I feel like I have the bruisers to contribute to this conversation.


Kyle Faget  3:30  
Thank you. Hi, I'm Kyle Faget. I'm the attorney up here with my notepad and pen. I'm a partner at Foley and Lardner. I sit in Boston, Massachusetts, I'm the co chair of our national healthcare and life sciences practice group. And I co chair our medical device area focus group there. My practice includes regulatory counseling, compliance, counseling, and a whole variety of contracting issues. So clinical trial agreements, manufacturing agreements, commercial agreements, kinda you name it. Before joining Foley about seven years ago, I was in house attorney at two pre commercial stage startup companies at Santa Fe, also at Boston Scientific. So yeah, I'll be here taking notes. 


Adam Rosenwach  4:25  
Great. So we cover everything here. We have startups VC side, big startups, early stage, and we even have a lawyer so we're ready to rock. Okay, so first, we wanted to find what it means. What does yes mean? Right, because the title of this panel is what happens after you get that first. Yes. But as I think we're about to hear, there's a lot of different things that happened before you even get a term sheet from that 'Yes'. So why don't we open up to the panel? What do you consider the moment where you actually get a yes that you are about to be funded, or at least like on a very certain track that fundings coming in.


Todd Usen  5:08  
So from my perspective, yes, there's probably a 'yes' from the investor. There's a 'yes' from the CEO. And then there's a real 'yes.' Yes. I mean, 'yes', to me is when the term, the term sheet sign, for the most part, because then diligence happens and things can go continue to go on. But in a bigger sense, yes, is when the money is in the bank.


Claire Masterson  5:31  
I was actually gonna say exactly that. So I'm a finance person. So for me, you know, I like to see the cache hit the bank, and the real close is the final 'Yes'. But, you know, term state term sheet is obviously incredibly important, you know, means that the investor has made that decision to progress. I think it's really, really important that before you get to that term state sheet stage, that you've actually had the opportunity to really go through a pretty deep level of diligence already, so that there's no surprises lurking whereby there might be any retreating of terms after that point. But certainly, I feel at that point, it's almost yours to lose as, as sort of a company that they're investing into and, and really, it's how well you can manage that process from that point to get them over that finishing line.


Adam Rosenwach  6:18  
So can you talk about a bit more the different kinds of commitments that you've gotten? Because Okay, so, yes, when we know what's going to happen, that's when money's in the bank? Definitely. What kind of different situations have you been through in the rest of the panel where you've gotten that first soft commitment? And how did you push that over the finish line to get the whole deal put together?


Kyle Faget  6:41  
So I think I'm more prodding you we talked a bit yesterday, when you get those soft, yeses, and how it can be difficult to get somebody to actually close? And how many investors will wait for that one closure to occur before they'll actually come to the table? And Claire, maybe you can add a little bit in your experience about that.


Claire Masterson  7:06  
Yeah, definitely. So, you know, on our experience, especially with market the way it is now there is even when investors have said yes, and they want to commit, you know, ICs will have different terms as to what that yes means. And let's say if you're raising 50 million of fundraising, and your lead tickets, 20 million of that, they may well have a stipulation to say, well, that's fine, but we're not closing until you've got 35 million syndicated. So that's where you can sometimes get into this sort of chicken and egg scenario where you're really trying to pull together the whole syndicate. So it's not just one 'Yes', you need. It's often several yeses all committed to closing at the same time. And, and kind of getting that commitment for the first person to pull the trigger can sometimes be a little like herding cats, quite frankly.


Todd Usen  7:56  
Yeah. And that, yes, today is even different than Yes, was two years ago. I mean, yes today, you have to you can't be surprised with the capital markets, where they are and what what's going on. And two years ago, or three years ago, I didn't think that it was going to be an investor that would do anything different than traditional liquidation preferences, or anything different with specific demands, because money was easy to get two or three years ago, if you just did your job. It's different now. So, you know, yes. Be careful what you sign up for, yes, we want that money, but know that what you're getting into? And remember, it is just a term sheet. It doesn't mean it's final. And you know, that's what I would say on a yes, because of all of a sudden you start getting these terms that make no sense for the company, and you believe in the company. You gotta keep moving. And it's, it's not always easy to look, look at a yes and actually walk away. But if yes, can turn out to be really dangerous process if you if you go on with the wrong partner that's truly looking out to just protect their money, and now looking out to help the entrepreneur build their business.


Kyle Faget  8:57  
So I think that's actually a really important point, particularly as you're maybe looking for the one that will sign and as you know, you're getting more desperate to actually find money, given that the market has shifted, understanding what it is that you're willing to give on before you go out to the market, I think is actually important. I mean, this is a principle that's true in contract negotiations to like, what's your giving point? What are you willing to give up? Is it a board seat that you're willing to give? Where are your flexibilities and then try to stick to that, to the extent that you can obviously, you know, depending on where you sit visa vie bargaining position, that may, you know, instruct your tolerance level or your risk level, but at the same time, at least pre defining for yourself when you go out, okay, here's where we're willing to go. And I say that just because I've seen clients over time, ultimately fold on things that were really important to them because they needed to actually get money in the bank. That's a super important thing obvious So you don't want to close the torso of the company. But having said that, you can have your company head in a totally different direction than you anticipated because you're willing to give in places that you didn't anticipate upfront.


Adam Rosenwach  10:15  
Diving a bit more into that into the terms. I'm curious, do investors and entrepreneurs typically have the same terms that they're not willing to negotiate on? Or do you find that they're different? Like, what are the most important things that you've seen as a lawyer from investors and the most important things from entrepreneurs. And then from you, I'm curious, but the most important things you look for in a term sheet are if we could start with with that, Kyle, I'm curious. 


Kyle Faget  10:40  
Yeah, I mean, I think, right. The two different parties. And again, this is always going to be true in a contractual negotiation, you're looking out for your interests. So liquidation preferences are going to make a difference, how much power and control you have, and you're willing to cede, those are things that matter equally, but in many ways, from an opposite perspective. And, again, something we sort of spoke about yesterday is understanding that your partner that you're bringing to the table, do they have the same exact goals that you do and goals for the company, and that can get reflected in the term sheet. And it can also make a huge difference after the money's in the bank and what that partnership looks like, moving forward.


Claire Masterson  11:24  
Yeah, agreed. And, you know, some maybe often overlooked terms and things like major investor writes level of reporting, and that sort of thing. And I think, you know, especially for early stage companies, really considering if you have a very minimal finance team and your investors want really detailed monthly reporting, you know, what impact is that going to have on your staffing and resourcing and your ability to spend time focusing on the business and growing the business rather than just serving, you know, investor reporting, and investors have a lot of different needs. And the other thing, you know, we talked a bit about board membership, you know, often the lead investor will take a board seat. So really understanding what is that? What is that investor bringing to your board? You know, do they have the right strategic contracts or commercial experience and, and one of the things I found is, you know, the board seat Belongs to the firm or the company that's invested. So, actually, the individual who ends up on your board, you might find that you actually need to be very specific and say, No, it's not appropriate for you to send an associate along, he's trying to get some experience. But actually, we have a very small board. And it's really important that those people can add the right level of value. And then the other thing you can end up with is a lot of board observers, which is definitely something in my experience that can have can either really enhance a boardroom where they are the right people, and really add a lot of depth and color to a conversation. But it can also, you know, mean that the board is much less effective, because you're not as focused. And so yeah, all of these sort of smaller points are actually really important. I think


Kyle Faget  13:01  
the board seat pieces is particularly important understanding, and even having a conversation to make sure you're on the same page with that investor about who's going to actually occupy that seat. Is it going to be somebody who sees and understands the business understands the industry and is actually in a position to move your business forward? Are they using that seat as a testing ground for one of their younger partners, and I have a client right now currently, that is experiencing that were a very green individuals sitting on the board and is sort of bowling around the company with very little understanding of what it means to actually occupy that position. And it's causing a lot of chaos. And, you know, again, they own the seat so they can fill it, but at the same time, if you can at least have a mutual understanding of what attributes are required for that seat that can go along with and it's,


Todd Usen  14:00  
it's really, I would jump on the board piece to it says a CEO, you're interviewing a venture capital or private equity firm just as much as they're interviewing you. And you know, I've had both situations one, you have lead investor who sends a really talented but not lead investor to sit on your board. It's shut down every vote, unless you present it everything to the lead the true head of the firm two days before because you will get back to we're not we're not putting our vote in for things that you had to vote on. The flip side is people that run the work for the partner that she was the best I've ever worked with, in the sense that she was a former operator of a major medtech company. She knew exactly the position I was in she knew exactly what we were doing. We set it up we were really excited. And then when they were a lead investor of around, and then the general practice practitioner, the whole four general partner I should say of the whole firm decided he was going to be on the board, brilliant, brilliant person, but didn't know the company wasn't the excitement that we had. And three years later, I don't know if he's ever stepped foot in the building of the company. And he does everything by zoom and really smart. I'm not beating anyone, I'm not at that company. And I'm not talking about who so I'm not going there. But it wasn't the reason that you so excited to work with the VC, it's really important because no one's interested, it doesn't help our resumes, or our companies to hear that, well, I sit on nine or 10 boards, that doesn't mean anything. I mean, that's, you know, so that's nine or 10 hours a month that you spend versus, you know, on different companies, and I lose that. So we're excited to work with VCs, but we really need VCs and that are real partners to the to the entrepreneur, and that that's dangerous. And a yes, you get a yes, sometimes you don't get to choose, they have a question for


Kyle Faget  15:46  
that. To that point, though, you know, I think even understanding why you're getting a 'Yes', what's the interest, and I have a situation with a client currently, where the investor, they're at a very unique inflection point where they're replacing the CEO, they're really at this, you know, about to really launch and create something huge. And the initials at the company all want to grow the company and make it a very big deal. But the investor, as it turns out, wanted to come in and build to the point where they can sell. So now they're in this place of trying to replace the CEO. And there's two totally different visions for what this company is going to be and do. On the one hand, like I say, we want to build this practice thing, particularly the first CEO, right, because the first CEO, this is typically their baby, they've grown it, they built it, there's a lot of pride involved. And so they want to hand this off to somebody who can take their vision and explode it into something fantastic. Whereas the investor, on the other hand, is like, Yeah, that's really great good for you. We want to flip this and get a return on our investment and sell this thing as of tomorrow. And that really, really impacts the credentials of the CEO that's going to come in. And is there any way to solve for this perfectly? Probably not. But if, in the initial conversations when they got that, yes, they understood, hey, we're investing because we want to flip this company, that would have been an important thing to know, you might have walked away from that particular investor, because that is not your vision, you want to build this thing into the multi million dollar corporation that's really successful. And for that particular CEO, you know, they can go to bed at night and say, Listen, I started something really, really big. And this is my dream. And so they're they're just totally diverting paths. And they're, again, you know, at stalemate with who's the next CEO, what are the credentials of the next CEO? And some of that might have been able to be avoided if, when they got the yes, they actually had a conversation. Why are you saying yes? What is your actual goal for this company? Absolutely.


Adam Rosenwach  17:56  
After after the yes, you should definitely understand what your investor wants, because the investor, they don't always want what's best for the company, their job is to do what's best for their investment. And sometimes those aren't exactly the same thing in the eyes of the founders or the current CEO, we do have a question.


Todd Usen  18:22  
I think it's a it's a good question. And I don't know if it's the accurate percentages, I was very happy and pleased that 100% of sign term sheets lead to because hopefully, if you do that, if you have a good enough relationship and do the work with the VC partner upfront, like if they don't just get signed in a few days, right, so these are the people that a new entrepreneur meets here, if you're looking to raise money this quarter, you should have met them a year ago at this meeting and build a relationship. And that's, you know, so you have to have that time. And so hopefully the people you're talking to you've built the relationship, they know you they're watching the company, they're keeping an eye. And so I think 100% can be signed, but there's still time and it's still, you know, a pain in the butt oftentimes, because everyone has different if you're if you're in the round, second phase, you're in a B round, or you're in in a prime round, your major investor rights and everyone that was early says, I put all the risk in this guy's coming in with all this money. They're not getting what I get. So you know, so there's an there all right. So but I do I believe 100% should be if the CEO is the kind that just wants to shop a term sheet. I actually think that's almost disrespectful. Also, I'm taking the venture side on that one, but it does happen. But you know, you hope if it's a good relationship, that should be 100%. My opinion.


Claire Masterson  19:44  
Yeah, look, I'd say we've also been pretty lucky in the sense that 100% of our term sheets have turned into final investments. We have had some back and forth you know, not everything is negotiated that terms, term sheet stage and there have been a lot Little bit of trading, just in one case a little bit on economics. But normally, that's the piece that is done at the terms sheet stage is pretty fixed. It can No, I would say, you know, in terms of timeline take, you know, anything from, I'd say, a month or six weeks to a few months between signing that term sheet, though with your lead lead investor in the final first close. And that's for sort of the reasons I mentioned before, you know, in terms of syndication, it depends, you know, how far along are you with those other conversations at the point of which the lead investor says yes, and the second thing is, there is quite a lot of due diligence, you know, as much as you want to get ahead of everything, in the first stages, they will go and they will look at everything from every senior leader employment contract to, you know, every contract that you have with all your underlying customers. So, you know, as long as everything there is, is ready, and you can, you know, backup every single number, you've shown your investors with the correct contracts and things, then you should be pretty confident, but you do need to be prepared and ready for that, because investors will want to see it. And so yeah, it's, and it can take some time to go through that process.


Adam Rosenwach  21:10  
There was oh, go ahead. Sorry,


Kyle Faget  21:11  
I was just gonna say, I think, ideally, if you have a good term sheet, and it actually reflects what it should reflect, which are the key terms, then there shouldn't be a problem getting it over the finish line, I think where things can fall apart, is if that term sheet doesn't actually express the important preferences of each of the parties. But having said that, they typically do, you know, you should have good counsel, you should be open in your conversations. But where I think it can really fall apart is in diligence. You know, if you're conducting diligence, post term sheet, and the investor, for example, uncovers for lack of a better way of putting it some significant warts, or there's something under the hood of the car that is really unsavory and wasn't disclosed, upfront in conversation, that can be really problematic. So that's where it's really on, you know, the company to disclose, hey, we do have a few concerns or being also strategic about how you how you enter into those initial contracts. So entering into a whole host of really unfavorable contracts, just to get out of the gates doesn't necessarily help you. Because then when you get to that diligence, and you have an investor that looks, you know, under the hood of the car, it's like, wait, you agreed that that we're doing you're giving up this amount and royalties, or what's the upside for us. So you do want to be a bit careful in the beginning, that you're actually agreeing to, you know, good, good contractual relationships so that you can leverage those. You know, when you're talking to VCs, and when they look under the hood of the car? 


Adam Rosenwach  22:59  
Yeah, I think we can all in this room agree, it feels like a big accomplishment when you get a term sheet. But a key thing is to make sure the correct amount of diligence was done, both on your side and the investor side. So after you get those term sheets, if more diligence is done, it's not going to change those terms. Because when that happens, it is it is always ugly, when terms are changed from the term sheets, the final documents follow up. Yeah. Yeah.


Todd Usen  23:33  
Even in the time that I was negotiating, these are my lawyer or lawyer, as a company was negotiating, the legal fees for the VC seem to go from more cover up to 50,000 turned out to 100,000 to end but then I, so I expected those extra fees, you know, to be part of it. But then I also realized that some part of me said, why would they charge us if they're trying to help us, but then I said, they're the ones giving me the money, they're just paying back themselves. So make sure I'm asking for the right amount up front. So if you ask for the right amount of front, knowing that you should probably put another, you know, not 10 but I mean, 1% If it's you talking millions, you know, put put numbers in there that you know, you're going to pay them back and don't fret over it. It doesn't if they ask for it great. You're paying yourself back and it's it's good. So I don't have a percentage, but I don't know, you might know specific more percentages, but it really fluctuated from I've seen everything from 50 to 125,000 Illegal fees to just close the deal.


Kyle Faget  24:33  
Yeah, that sounds fair. I mean, look, it also depends on the market. Right? So when money was easy, legal fees were not as extensive in large part because people were screaming through diligence we don't really care like money is easy. We're gonna go we're gonna sign everything and move forward valuations of companies were through the roof. Everybody was super happy. And as the market shifts and people are being more careful and conscious, there's going to be increased diligence, which just ultimately means increased legal fees. Having said that, there are ways I think that you can manage counsel. And I will say that, you know, having a point person for diligence, making sure that you have called the appropriate documents sets, and they're set up and organized in the data room in a logical way so that their counsel can come in and do an efficient review of your documents. And that avoids, for example, their side calling random people in the company, oh, we have a question about X, Y, and Z, I want to talk to your quality person, I want to talk to your CFO, I want to talk to set up your team that's going to be available during diligence to actually be responsive to requests, make sure you have like I say the documents called in in the data room in a very logical way. These are things that you can do to help create efficiencies in that process. Because sitting on the attorney side, when all of this is sort of gummed up. It's up to the attorneys then to try and unscramble it and sit on the line with opposing counsel to say, what do you expect to see what do you want to see, oh, this was there, this was there. And then explaining, oh, when you talk to that random person in the company, and they said X, Y, and Z, actually, they weren't operating with full information, you need to talk to this other person. And it's ultimately the attorneys that are quarterbacking that at, you know, whatever rate, they're quarterbacking that add $500 an hour if it's going to be a young associate up to you know, $2,000 an hour if it just ends up being you know, a senior partner. So there's ways you can manage costs by just being thoughtful at the outset.


Adam Rosenwach  26:51  
This, this is gonna be a bold statement. But I actually believe that you can reduce your legal fees by 50%, by just managing the process and owning and being the center of communication and not giving that job to them. Great. I mean, I'll always have a conversation. First thing, what do you expect this to cost and legal costs for closing. And I mean, it's not particularly nice, but you have to look at your legal bills and see if you're paying for the training of a much younger associate. But by the way, we've closed two or three deals in the past year, and the legal fees have on all of those deals been over $150,000 in an early stage. So I would expect that right now, in the US for closing deals, I can't say one


Claire Masterson  27:37  
thing I would say for early around investors is, you know, legal fees are probably not the area to skimp on when it comes to these documentation. It's so important that you have the right counsel in your corner, when those documents are drafted, you know, your series A documents are going to be the basis for your series B documents, and then you'll see documents and then your D documents, new investors tend to come in and start from the documents that are already in place. And yes, make changes and if necessary to those. But you know, you can also hold up the process, you know, going back to that original question, if there are strange rights, that look look fine, because it's a Series A and you've got one big investor in there. But you know, certain blocking rights and different rights for sort of that original first investor can be very problematic when you're getting into a series B and Series C, if those rights haven't fallen away, for example, or they maintain them, because it's something that other investors will come in, and that final diligence process, and it may just be uncomfortable, and then you might have to start retraining with that first investor. So actually getting it right at the very beginning, will save you so much time when you get further down the line.


Adam Rosenwach  28:52  
Because when you're closing that deal, that first round, you're not only closing that round, but you are setting the terms, or at least the starting point of terms for all of your future rounds. And on that. So in these terms, a lot of it comes down to control that can cause issues later on what have you all seen as points that have held up deals once you get into your final closing doc and instead of been real contention points that are not typically negotiated in the term sheet.


Todd Usen  29:18  
Major investor rights and based on each round, so you know, as your first round, that doesn't matter, because it's your first round. But then your first round investors, rightfully so are taking a bigger risk. And you get bigger investors coming in to lead additional rounds, which is great, but then they they want, you know, major, certain major investor rights and then all of a sudden the percentage of money that's in from some of your early investors doesn't come anywhere near the money. It's just the know that seems to be the one sticking point always. And then the the board seats because again, if you have an early investor that even led your first round, and they're on your board. But they don't put anything in for your next one or two or three rounds, I'm not taking them off the board. But all of a sudden, you have a new investor coming in with a big boatload of money and your B, or C. And they're saying we're going to be, we have this seat, and we'll maybe two seats, and we only want a board of up to this many. Someone is going off the board. Yeah. And they know it, but it's in there. So that's usually the those are the two to me that I've seen.


Claire Masterson  30:25  
I say very similar experience in that sense. Also, I think, where you might have, especially in the early days, I think it's quite common for a strategic to lead early rounds, rather than financial investors quite often. And, and sometimes they come with their own unique terms, especially when they are combined with some sort of commercial arrangement. They can cause difficulties, especially if you know, there are, let's say, even if it's a perceived block, I would say often it's not really a block, but a perceived block on working with other companies in the same space or, you know, some sort of conflict that can sometimes create issues down the line as well, I think. 


Kyle Faget  31:12  
That.


Todd Usen  31:15  
I would say just one thing with the board. And for any even earlier stage entrepreneurs, if you can get an operator on the board, in addition to your venture partners, absolutely do it early, because you're going to just run out of space, and then it's no disrespect, it's Venture Partners, they have to protect their money, that that really is their job, they want to protect the company, the best ones and demonstrate that and are great helps. But if you don't have a real partner on your board, it's really difficult to just run a business without any other operators that have their independent directors. So I would do that early, no matter how early stage you are.


Adam Rosenwach  31:52  
So we only have a couple minutes, are there any questions there?


Todd Usen  32:05  
Well shopping and you can still put dates to different groups, you really have multiple people that you know, want us submit a term sheet, you basically said, Hey, we're accepting, it's almost like selling a house right now. It's like, you're going to do three days of open houses. And we're going to accept our offers on Tuesday after the Sunday. And so it's a buyers market, assuming it's a seller's market. But same thing, if you really know that you just you set the expectations that you know, we're accepting term sheets by this date. And this way you if you think you're getting multiple, I just feel if you're worth this, my personal opinion doesn't mean it's right or wrong. It's just if I got a term sheet from someone that I've been working with the last month, and they've always said that we will only do this if we lead. I don't feel I feel it's not it's disrespectful for me personally to shop it. I'm sure many people say you're crazy, Todd, because you could do so much better. If you do shop, I just don't.


Adam Rosenwach  32:59  
Depends what you're shopping for it too. I mean, right valuation and liquidation pros, all these things. They're important, but I actually really do believe it's much more important that you're shopping for the best investor and partner in this company. Because all those things don't matter when shit hits the fan. And it always does. It matters that you have good partners at that stage. So the term sheet shopping?


Claire Masterson  33:27  
I probably agree to you know, I do think that, you know, small horse trading on valuation, for example, or what have you is, yes, it will help you in the short term. But actually, in the longer term, what's more important is knowing that that lead investor, and maybe the one or two larger investors around there, and for you in the long haul, will be a good partner. You know, actually that was the question is, Who are you getting into bed with? Is this a one off ticket, they might give you a massive ticket, but it's a one off, and they're not offering you any strategic value over and above that, where you might be better off going with someone who is slightly more conservative on the valuation, that actually is going to put money in every single round for the next however many rounds, which when you're trying to syndicate and will be incredibly valuable. When you get there, you know, and we'll support you. 


Todd Usen  34:16  
That's a huge, huge point to know what kind of dry powder because look at this market. If I'm a VC, I'm protecting my portfolio companies first you have to. Yeah, if you if you know and so it's nice to know that they can continue that to your point.


Kyle Faget  34:30  
I thinkif anything, and this is reflected in the legal fees or shopping, term sheets or anything else. It's when you're thinking about money, of course you want to be conservative, and of course you want to be thoughtful, but I guess my best advice is don't be penny wise and pound foolish. Make sure that you're actually as you say getting into bed with the right partner, somebody who shares your vision that you can imagine working with in the long term And that sometimes is worth letting go. A few things here and there and saying, you know, did I get economically the absolute best deal I could have possibly gotten? Maybe not. But on the reverse side, maybe you also got the best partner that shares your strategic vision and that in the long run is worth everything.


Adam Rosenwach  35:23  
So this sign is yelling at me that we're 46 seconds over. So we're gonna wrap. Thank you all. This was super, super helpful, a lot of great information. I hope this was beneficial for everybody. And yeah, thank you. Thanks for joining us.

back Back to all attendees close
Adam Rosenwach

Adam Rosenwach

Chief Business Officer, Deerfield Catalyst

Since 2016, I have led fundraising and closing on over $100M of seed/early stage Medtech deals resulting in the formation and development of seven new companies.

I joined the Coridea team in 2014 and currently function as the Chief Business Officer of Deerfield Catalyst, an incubator partnership between Coridea and Deerfield Management. My current responsibilities include innovation management, managing all financial aspects of the incubator and its portfolio companies, and business development.

Prior to my career in healthcare, I attended the Berklee College of Music and continued my journey producing music and developing artists through my production company that I began at age 16. During this period of time I also pioneered music technology programs in public schools throughout New York City and founded a travel consulting company to assist clients in acquiring and maximizing credit card points and miles. I am a board member of the Bronx Arts Ensemble, where I sit on the education committee.

  • linkedin
  • Website website
back Back to all attendees close

Adam Rosenwach

Chief Business Officer, Deerfield Catalyst

Since 2016, I have led fundraising and closing on over $100M of seed/early stage Medtech deals resulting in the formation and development of seven new companies.

I joined the Coridea team in 2014 and currently function as the Chief Business Officer of Deerfield Catalyst, an incubator partnership between Coridea and Deerfield Management. My current responsibilities include innovation management, managing all financial aspects of the incubator and its portfolio companies, and business development.

Prior to my career in healthcare, I attended the Berklee College of Music and continued my journey producing music and developing artists through my production company that I began at age 16. During this period of time I also pioneered music technology programs in public schools throughout New York City and founded a travel consulting company to assist clients in acquiring and maximizing credit card points and miles. I am a board member of the Bronx Arts Ensemble, where I sit on the education committee.

  • linkedin
  • Website website
Adam Rosenwach
back Back to all attendees close
Todd Usen

Todd Usen

President & CEO, Minerva Surgical

Currently the President and Chief Executive Officer of Minerva Surgical, a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Executive leader skilled in building, restructuring and growing commercial and operational organizations in both top and bottom line. Responsible for developing and directing both short- and long-term strategic vision, product development, logistics, distribution, go-to market strategy, and M&A activities. Management development advocate. Experience managing multi-billion-dollar P&L's. Current board director of Alesi Surgical, Mass Medical and Surgical Disruptive Technology Summit.

  • linkedin
  • Website website
back Back to all attendees close

Todd Usen

President & CEO, Minerva Surgical

Currently the President and Chief Executive Officer of Minerva Surgical, a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Executive leader skilled in building, restructuring and growing commercial and operational organizations in both top and bottom line. Responsible for developing and directing both short- and long-term strategic vision, product development, logistics, distribution, go-to market strategy, and M&A activities. Management development advocate. Experience managing multi-billion-dollar P&L's. Current board director of Alesi Surgical, Mass Medical and Surgical Disruptive Technology Summit.

  • linkedin
  • Website website
Todd Usen
back Back to all attendees close
Claire Masterson

Claire Masterson

CFO, Caresyntax

Experienced CFO with experience of working in Digital Healthcare, venture/PE backed businesses and Alternative Investments. Skilled in all aspects of Financial management including Fundraising, Listed and private company financial reporting, budgeting, cash management, restructuring, SaaS businesses, KPI reporting, Investor relations, FP&A, mergers and acquisitions and Valuations.

 

  • linkedin
  • Website website
back Back to all attendees close

Claire Masterson

CFO, Caresyntax

Experienced CFO with experience of working in Digital Healthcare, venture/PE backed businesses and Alternative Investments. Skilled in all aspects of Financial management including Fundraising, Listed and private company financial reporting, budgeting, cash management, restructuring, SaaS businesses, KPI reporting, Investor relations, FP&A, mergers and acquisitions and Valuations.

 

  • linkedin
  • Website website
Claire Masterson